A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis

Inclusion Criteria:

• Should have all the following: A confirmed diagnosis of moderate-to-severepalmoplantar-non-pustular psoriasis with palm and/or sole involvement and at least oneplaque at a body site other than the palms and soles for at least 6 months, to confirma diagnosis of chronic psoriasis; psoriatic area and severity index (PASI) scoregreater than or equal to (>=) 3 and less than (<) 10 at screening and at baseline;Palmoplantar Investigator Global Assessment (ppIGA) score >=3 at screening and atbaseline
• Should be eligible to receive biological treatments; only participants who are naiveto biological treatments can be included
• A woman of childbearing potential must have a negative urine pregnancy test atscreening and at Week 0
• Agree not to receive a live virus or live bacterial vaccination during the study, orwithin 12 weeks after the last administration of study intervention
• Agree to avoid prolonged sun exposure and agree not to use tanning booths or otherultraviolet (UV) light sources from the first administration of study interventionthrough 12 weeks after the final dose of study intervention (Week 56)

Exclusion Criteria:

• Currently has palmoplantar pustulosis, pustular psoriasis, or any other forms otherthan plaque-type psoriasis (e.g, erythrodermic, guttate), or hyperkeratotic eczema
• Has current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation ofpsoriasis from beta blockers, calcium channel blockers, or lithium)
• Has received prior systemic treatment with biological agents or Janus Kinase (JAK)inhibitors
• Has had prior exposure, known and reported intolerance to guselkumab or excipients, orineligible to treatment with biological agents
• Is infected with human immunodeficiency virus (HIV, positive serology for HIVantibody)